Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $209,397.84 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 3,019 shares of PTC Therapeutics stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $69.36, for a total transaction of $209,397.84. Following the completion of the transaction, the insider owned 77,122 shares in the company, valued at approximately $5,349,181.92. This represents a 3.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Eric Pauwels also recently made the following trade(s):

• On Monday, January 12th, Eric Pauwels sold 1,024 shares of PTC Therapeutics stock. The stock was sold at an average price of $78.70, for a total value of $80,588.80.
• On Friday, January 9th, Eric Pauwels sold 1,722 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.41, for a total value of $133,300.02.
• On Thursday, January 8th, Eric Pauwels sold 4,602 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.50, for a total value of $352,053.00.
• On Wednesday, January 7th, Eric Pauwels sold 1,352 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total value of $104,752.96.
• On Tuesday, January 6th, Eric Pauwels sold 1,789 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $137,663.55.
• On Friday, December 19th, Eric Pauwels sold 20,508 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.26, for a total value of $1,584,448.08.
• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.43, for a total transaction of $3,039,074.70.
• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.06, for a total transaction of $240,342.12.

PTC Therapeutics Stock Performance

Shares of PTC Therapeutics stock opened at $70.66 on Monday. The company has a market cap of $5.85 billion, a P/E ratio of 9.13 and a beta of 0.48. The firm has a fifty day moving average of $74.91 and a two-hundred day moving average of $68.14. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). The firm had revenue of $164.68 million during the quarter, compared to analysts’ expectations of $281.45 million. PTC Therapeutics had a net margin of 39.44% and a negative return on equity of 362.45%. The firm’s revenue was down 22.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.85) EPS. As a group, equities analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jefferies Financial Group Inc. acquired a new stake in PTC Therapeutics in the 3rd quarter valued at about $97,252,000. Janus Henderson Group PLC lifted its holdings in shares of PTC Therapeutics by 28.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock valued at $368,587,000 after purchasing an additional 1,077,776 shares in the last quarter. State Street Corp grew its position in shares of PTC Therapeutics by 34.2% in the fourth quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock valued at $319,497,000 after purchasing an additional 1,071,343 shares during the last quarter. Toronto Dominion Bank grew its position in shares of PTC Therapeutics by 27.5% in the fourth quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock valued at $314,339,000 after purchasing an additional 891,690 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of PTC Therapeutics by 4,013.1% during the 4th quarter. BNP Paribas Financial Markets now owns 828,662 shares of the biopharmaceutical company’s stock worth $62,945,000 after purchasing an additional 808,515 shares in the last quarter.

Wall Street Analyst Weigh In

PTCT has been the topic of a number of analyst reports. Wells Fargo & Company decreased their price target on PTC Therapeutics from $93.00 to $86.00 and set an “overweight” rating on the stock in a research note on Friday. Barclays upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $68.00 to $119.00 in a research report on Tuesday, January 27th. Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 price target on shares of PTC Therapeutics in a research note on Thursday, January 8th. Wall Street Zen cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Royal Bank Of Canada lowered their target price on shares of PTC Therapeutics from $87.00 to $82.00 and set a “sector perform” rating on the stock in a research report on Friday. Ten analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, PTC Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $80.73.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.